Posted On: 08/03/2014 3:58:19 PM
Post# of 273254
Ico Therapeutics (ICOTF) 0.0540 $ICOTF
iCo Therapeutics Inc. - No Material Change
CNW Group - Tue Jul 15, 12:29PM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), at the request of IIROC, confirms that there is no material change that would account for the recent increase in market activity.
Immune Appoints Cameron Durrant, MD, MBA to Board of Directors
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company" appointed Dr. Cameron Durrant as new independent director. Dr. Durant becomes a Member of the Compensation Committee and the R&D Committee.
iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders
PR Newswire - Mon Jun 30, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) today announced that all nominees listed in the management information circular datedMay 28, 2014were elected as directors at its 2014 Annual Meeting of Shareholders, held onFriday, June 27, 2014. On a vote by ballot, the following five nominees proposed by management were elected as Directors of iCo Therapeutics to serve until the Company's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows:
iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema
CNW Group - Mon Jun 09, 7:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) today announced top-line results related to the eight month visual acuity (VA) primary endpoint for subjects enrolled in the Phase 2 iDEAL Study, conducted in collaboration with JDRF, evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME).
Immune Appoints Gad Berdugo to Board of Directors and Karin Hehenberger, M.D., Ph.D to Senior Vice President
GlobeNewswire - Fri Jun 06, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company" appointed Mr. Gad Berdugo as new independent director and Karin Hehenberger, M.D., Ph.D., as Senior Vice President, Medical Affairs and Corporate Communications.
iCo Therapeutics Announces First Quarter 2014 Financial Results
PR Newswire - Thu May 29, 4:00PM CDT
iCo Therapeutics ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended March 31, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS" .
Immune Pharmaceuticals Announces First Quarter 2014 Financial Results
GlobeNewswire - Wed May 21, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) and (Nasdaq:IMNP) ("Immune" or "the Company" announced today its financial results for the three month period ended March 31, 2014.
Immune CEO Announces New Operational Leadership Team
GlobeNewswire - Wed Apr 02, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today the addition of two new senior members to its management team.
Immune Pharmaceuticals Announces $11.7 Million Private Placement Financing
GlobeNewswire - Sun Mar 09, 11:01PM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today that it has entered into a definitive agreement with investors for the sale of $11.7 million of preferred stock and warrants in a private placement transaction (expected to result in approximately $11 million in net proceeds to Immune, after the subtraction of transaction fees and expenses). Additional details regarding the material terms of the transaction, which is expected to close on March 11, 2014, will be disclosed in a Current Report on Form 8-K expected to be filed this day.
iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study
CNW Group - Wed Mar 05, 6:00AM CST
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) has announced the final month eight patient visit in the iDEAL Study. This US Phase 2 investigator-sponsored study is evaluating the efficacy and safety of iCo-007 after repeated injections in patients with Diabetic Macular Edema (DME). The study's primary endpoint is change in visual acuity from baseline to month eight, followed by secondary endpoints at month twelve. Next steps include data queries and subsequent data lock. Once these activities are complete, the results will be analyzed and top-line results will be made public.
iCo Therapeutics Announces DTC Approval
PR Newswire - Tue Feb 25, 12:15PM CST
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) today announced that its United States trading symbol ICOTF has received approval from The Depository Trust Company (the "DTC" , thus providing the Company with DTC eligibility.
IIROC Trade Resumption / L'OCRCVM permet la reprise de la négociation - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 9:20AM CST
Trading resumes in / Reprise des negociations pour:
iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing
PR Newswire - Mon Jan 27, 9:03AM CST
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) announced today that it has closed its previously announced overnight marketed offering of equity securities (the "Offering" . Pursuant to the Offering, iCo issued 16,206,483 units of the Company ("Units" at a price of $0.4165 per Unit for aggregate gross proceeds of C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share" and three-quarters of one common share purchase warrant (each whole warrant, a "Warrant" . Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one Common Share for a period of five years following the date of issuance of the Warrant.
IIROC Trading Halt / Suspension de la négociation par l'OCRCVM - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 8:43AM CST
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants :
iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing
PR Newswire - Wed Jan 22, 7:42AM CST
iCo Therapeutics Inc. ("iCo" or the "Company" (TSX-V: ICO) (OTCQX: ICOTF) is pleased to announce today that the Company has priced its previously announced overnight marketed offering of equity securities (the "Offering" . Pursuant to the Offering, iCo will issue an aggregate of up to 16,206,483 units of the Company ("Units" at a price of C$0.4165 per Unit for aggregate gross proceeds of approximately C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share" and three-quarter of one common share purchase warrant (each whole warrant, a "Warrant" . Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one common share of the Company (a "Warrant Share" for a period of five years following the closing of the Offering.
iCo Therapeutics Inc. - No Material Change
CNW Group - Tue Jul 15, 12:29PM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), at the request of IIROC, confirms that there is no material change that would account for the recent increase in market activity. Immune Appoints Cameron Durrant, MD, MBA to Board of Directors
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company"
appointed Dr. Cameron Durrant as new independent director. Dr. Durant becomes a Member of the Compensation Committee and the R&D Committee. iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders
PR Newswire - Mon Jun 30, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF) today announced that all nominees listed in the management information circular datedMay 28, 2014were elected as directors at its 2014 Annual Meeting of Shareholders, held onFriday, June 27, 2014. On a vote by ballot, the following five nominees proposed by management were elected as Directors of iCo Therapeutics to serve until the Company's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows: iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema
CNW Group - Mon Jun 09, 7:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF) today announced top-line results related to the eight month visual acuity (VA) primary endpoint for subjects enrolled in the Phase 2 iDEAL Study, conducted in collaboration with JDRF, evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). Immune Appoints Gad Berdugo to Board of Directors and Karin Hehenberger, M.D., Ph.D to Senior Vice President
GlobeNewswire - Fri Jun 06, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company"
appointed Mr. Gad Berdugo as new independent director and Karin Hehenberger, M.D., Ph.D., as Senior Vice President, Medical Affairs and Corporate Communications. iCo Therapeutics Announces First Quarter 2014 Financial Results
PR Newswire - Thu May 29, 4:00PM CDT
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended March 31, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS" . Immune Pharmaceuticals Announces First Quarter 2014 Financial Results
GlobeNewswire - Wed May 21, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) and (Nasdaq:IMNP) ("Immune" or "the Company"
announced today its financial results for the three month period ended March 31, 2014. Immune CEO Announces New Operational Leadership Team
GlobeNewswire - Wed Apr 02, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today the addition of two new senior members to its management team.
Immune Pharmaceuticals Announces $11.7 Million Private Placement Financing
GlobeNewswire - Sun Mar 09, 11:01PM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today that it has entered into a definitive agreement with investors for the sale of $11.7 million of preferred stock and warrants in a private placement transaction (expected to result in approximately $11 million in net proceeds to Immune, after the subtraction of transaction fees and expenses). Additional details regarding the material terms of the transaction, which is expected to close on March 11, 2014, will be disclosed in a Current Report on Form 8-K expected to be filed this day.
iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study
CNW Group - Wed Mar 05, 6:00AM CST
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF) has announced the final month eight patient visit in the iDEAL Study. This US Phase 2 investigator-sponsored study is evaluating the efficacy and safety of iCo-007 after repeated injections in patients with Diabetic Macular Edema (DME). The study's primary endpoint is change in visual acuity from baseline to month eight, followed by secondary endpoints at month twelve. Next steps include data queries and subsequent data lock. Once these activities are complete, the results will be analyzed and top-line results will be made public. iCo Therapeutics Announces DTC Approval
PR Newswire - Tue Feb 25, 12:15PM CST
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF) today announced that its United States trading symbol ICOTF has received approval from The Depository Trust Company (the "DTC" , thus providing the Company with DTC eligibility. IIROC Trade Resumption / L'OCRCVM permet la reprise de la négociation - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 9:20AM CST
Trading resumes in / Reprise des negociations pour:
iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing
PR Newswire - Mon Jan 27, 9:03AM CST
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF) announced today that it has closed its previously announced overnight marketed offering of equity securities (the "Offering" . Pursuant to the Offering, iCo issued 16,206,483 units of the Company ("Units" at a price of $0.4165 per Unit for aggregate gross proceeds of C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share" and three-quarters of one common share purchase warrant (each whole warrant, a "Warrant" . Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one Common Share for a period of five years following the date of issuance of the Warrant. IIROC Trading Halt / Suspension de la négociation par l'OCRCVM - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 8:43AM CST
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants :
iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing
PR Newswire - Wed Jan 22, 7:42AM CST
iCo Therapeutics Inc. ("iCo" or the "Company"
(TSX-V: ICO) (OTCQX: ICOTF) is pleased to announce today that the Company has priced its previously announced overnight marketed offering of equity securities (the "Offering" . Pursuant to the Offering, iCo will issue an aggregate of up to 16,206,483 units of the Company ("Units" at a price of C$0.4165 per Unit for aggregate gross proceeds of approximately C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share" and three-quarter of one common share purchase warrant (each whole warrant, a "Warrant" . Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one common share of the Company (a "Warrant Share" for a period of five years following the closing of the Offering.
(0)
(0)Scroll down for more posts ▼
